CPC-006 Adequacy of Criteria For Starting Natalizumab in Patients with Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Use of natalizumab in multiple sclerosis patients.
Natalizumab is a monoclonal antibody indicated in Canada as monotherapy for the treatment of multiple sclerosis (MS) patients with relapsing-remitting disease. The phase III clinical trial of natalizumab monotherapy demonstrated substantial improvements in clinical and magnetic resonance imaging (MRI) parameters in patients with relapsing-remitting MS, with statistically significant reductions ...
متن کاملNatalizumab in pediatric multiple sclerosis patients.
Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associat...
متن کاملGlioblastoma in natalizumab‐treated multiple sclerosis patients
We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade ...
متن کاملUse of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.
Natalizumab is a monoclonal antibody indicated in Canada as monotherapy for the treatment of multiple sclerosis (MS) patients with relapsing-remitting disease. Although natalizumab has been available in Canada since 2006, there remain elements of uncertainty among community and academic neurologists on how best to use this drug in clinical practice. The following recommendations relating to the...
متن کاملNatalizumab for relapsing multiple sclerosis.
To the Editor: As Ropper pointed out in his editorial (March 2 issue),1 the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is “a potent treatment for multiple sclerosis” may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebocontro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.463